Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 6/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12381935 | 0.86 | NPC1 (0.37) | NPC1MAPTDGAT1HTT | |
| SCHEMBL1857151 | 0.85 | NPC1 (0.37) | NPC1MAPTDGAT1HTT | |
| SCHEMBL1857284 | 0.83 | DGAT1 (0.36) | NPC1MAPTDGAT1HTT | |
| Lithium Ion SCHEMBL17764484 | 0.83 | MAPT (0.37) | NPC1MAPTDGAT1 | |
| Potassium Ion SCHEMBL3543627 | 0.82 | NPC1 (0.34) | NPC1MAPTDGAT1 | |
| SCHEMBL7950529 | 0.74 | MAPT (0.35) | NPC1MAPTDGAT1HTT | |
| Potassium Ion SCHEMBL2147280 | 0.74 | F2RL1 (0.41) | NPC1MAPTDGAT1 | |
| SCHEMBL15471725 | 0.74 | DGAT1 (0.41) | NPC1MAPTDGAT1HTT | |
| Potassium Ion SCHEMBL4187966 | 0.73 | NPC1 (0.34) | NPC1MAPTDGAT1 | |
| Lithium Ion SCHEMBL17764412 | 0.72 | NPC1 (0.35) | NPC1MAPTDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296726-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-29 | — | — | US | disclosed |
| US-20150051196-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-19 | — | — | US | disclosed |
| US-8895584-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-25 | — | — | US | disclosed |
| US-20140243382-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-28 | — | — | US | disclosed |
| US-8759347-B2 | Inhibitors of C-FMS kinase | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | disclosed |
| US-20130281475-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-24 | — | — | US | disclosed |
| US-8481564-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-07-09 | — | — | US | disclosed |
| US-20110195960-A1 | INHIBITORS OF C-FMS KINASE | ILLIG CARL R | 2011-08-11 | — | — | US | disclosed |
| US-7973035-B2 | Inhibitors of C-FMS kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-07-05 | — | — | US | disclosed |
| EP-2021335-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-25 | — | — | EP | disclosed |
| EP-2021335-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF C-FMS KINASE | Janssen Pharmaceutica, N.V. (BE) | 2009-02-11 | — | — | EP | disclosed |
| US-20080275031-A1 | 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | ILLIG CARL R | 2008-11-06 | — | — | US | disclosed |
| US-7414050-B2 | e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-19 | — | — | US | disclosed |
| WO-2007124316-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| US-20070249593-A1 | e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281475-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | NPC1 4547/4885MAPT 75/4885DGAT1 3518/4885 |
| US-20070249593-A1 | e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | MUSK, CHUK, PNCK | NPC1 4209/4885MAPT 166/4885DGAT1 3459/4885 |
| US-20150051196-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | NPC1 4547/4885MAPT 75/4885DGAT1 3518/4885 |
| US-20140243382-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | NPC1 4547/4885MAPT 75/4885DGAT1 3518/4885 |
| US-20110195960-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | NPC1 4547/4885MAPT 75/4885DGAT1 3518/4885 |
| US-20080275031-A1 | 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | MUSK, CHUK, CAMK4 | NPC1 4063/4885MAPT 128/4885DGAT1 3481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.